Dr. Elizabeth Brint graduated with a BSc in Biochemistry from the University of Sussex, UK and a PhD from Trinity College Dublin. After post doctoral studies performed jointly between Trinity College Dublin and Xoma Ltd, a San Francisco based pharmaceutical company, she moved to UCC where she was a postdoctoral researcher in the APC Institute and is now a lecturer in the Pathology Department.

Research

Dr. Brint's main research interests focus on characterisation of immune signalling pathways and how these are dysregulated in disease with a specific focus on diseases of the intestine. She is interested in identifying mechanisms of regulation of immune receptors in the intestine as disruption of these mechanisms may lead to the development of Irritable Bowel Syndrome, Inflammatory Bowel Diseases (IBDs) and colon cancer. Through the development of recent collaborations, she has developed an emerging interest in the role of the immune system in the pathogenesis of cancer. Her work has been published in journals such as Nature Immunology, PNAS, Journal of Immunology and the British Journal of Cancer.